Hitachi Aloka, the innovator in ultrasound is the longest operating ultrasound company in the world with its international headquarters located in Tokyo, Japan and U.S. headquarters in Wallingford, CT. The history of Hitachi Aloka began in 1950 when the medical equipment department of Japan Radio Company became the independent company, Medical and Physical Institute Co., Ltd. In 1960, Hitachi Aloka developed the world’s first commercially available diagnostic ultrasound system.
To learn more, please visit
www.hitachi-aloka.com
The Janssen Pharmaceutical Companies of Johnson & Johnson‘s mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented by bringing cutting-edge science and the most creative minds in the industry together to think differently about diseases. The company aims to not only innovate but also to empower people with the tools they need to make informed decisions and achieve the best possible results for their health.
To learn more, please visit
www.janssen.com/
Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our long legacy of engineering excellence and our pioneering approach to developing the latest advancements, we are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services.
To learn more, please visit
usa.siemens.com/Healthineers
SILVER LEVEL SPONSOR
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is funded by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC).
To learn more, please visit www.blueearthdiagnostics.com.
Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Today, Myriad is expanding its reach and increasing its impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
To learn more, please visit
www.myriad.com/
Royal Philips of the Netherlands is a diversified technology company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Philip’s commitment is to deliver new healthcare and lighting technologies, as well as innovative and locally relevant consumer products that make a real difference to our customers, consumers and stakeholders across the globe.
Invivo is a business of Royal Philips (NYSE: PHG; AEX: PHIA) and has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices.
To learn more, please visit
http://www.invivocorp.com/
BRONZE LEVEL SPONSORS
Exact Imaging’s ExactVu™ micro-ultrasound system for prostate imaging and targeted biopsy provides a 300% improvement in resolution over current standard-of-care ultrasound systems and superior resolution to MRI. Urologists can visualize suspicious regions and actually target (instead of blindly place) biopsies to those regions, aided by the PRI-MUS™ evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (ie. prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform.
To learn more, please visit http://www.exactimaging.com/
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
To learn more, please visit
www3.gehealthcare.com
me
Genomic Health is the world’s leading provider of genomic-based diagnostic tests that address both the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient’s journey, from diagnosis to treatment selection and monitoring.
Our Mission: To transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
Our Vision: To revolutionize the treatment of cancer throughout the patient journey.
Our Vision: To revolutionize the treatment of cancer throughout the patient journey.
ad
To learn more, please visit http://www.genomichealth.com
moooo
KOELIS, The Prostate Care Company has assisted urologists and radiologists worlwide in their routine clinical practice since 2006 with the latest technology in image-guided interventions. Looking for developing new paradigms in prostate cancer management, KOELIS team continuously innovates for helping physicians to gain confidence and accuracy in diagnosis and targeted treatments. Thanks to cutting-edge imaging tools like Trinity® system and the exclusive high-detailed and recordable 3D prostate cartography, KOELIS guarantees quality control and patient compliance at every step of the whole prostate cancer management, from biopsy and active surveillance to treatment and follow-up.
bloop
To learn more, please visit http://koelis.com/en/
Go Eags
Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to target and treat cancer. The Company’s pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM), and 3) imaging analysis tools. Progenics’ first commercial product, RELISTOR®(methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
lol
To learn more, please visit http://www.progenics.com/
The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.
To learn more, please visit
www.massachusettsprostatecancercoalition.org
ScanMed‘s Core Value: The Image Is Everything. ScanMed is committed to constantly improving all of their MRI coils to ensure that physicians, surgeons, radiologists, MRI technicians, and medical researchers are given the most precise, accurate, and high quality images they need to make life-saving decisions.
To learn more, please visit http://www.scanmed.com/
EXHIBITORS
meow
Armune BioScience is a medical diagnostics company operating a high complexity CLIA laboratory in Ann Arbor, MI. Armune’s proprietary technology captures the body’s immune system response to cancer. In April 2015, Armune launched its first commercial product; Apifiny® is the only cancer specific, non-PSA blood test available in the world that may aid clinicians in the assessment of risk for the presence of prostate cancer.
To learn more, please visit http://armune.com/
como estas
GenomeDx Biosciences is transforming patient management by putting usable genomic information in the hands of physicians and their patients. GenomeDx has developed the Decipher® Prostate and Bladder Cancer Classifier tests, genomic tests that provide treatment information for urologic cancer patients.
hola
To learn more, please visit https://genomedx.com/decipher-test/decipher-prostate-cancer-test/
The Profound Medical team is committed to the effort to achieve a new therapeutic standard in prostate cancer. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate cancerous prostate tissue with precision; a tomorrow where patients have access to a safe, fast and effective treatment option, so they can quickly return to their daily lives.
Established in 2008, Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO® is CE Marked and Profound is sponsoring a multicenter, prospective FDA-registered clinical trial, TACT.
To learn more, visit
www.profoundmedical.com